Express Pharma
Home  »  Latest Updates  »  DRL in agreement with Integra LifeSciences

DRL in agreement with Integra LifeSciences

20

To market and distribute DuraGen Plus and Suturable DuraGen Dural Regeneration in India

Dr Reddy’s Laboratories (DRL) and Integra LifeSciences Holdings Corporation, a leading global medical technology company, have entered into an exclusive distribution agreement. Under the agreement, DRL will market and distribute DuraGen Plus and Suturable DuraGen Dural Regeneration Matrices for use in patients in India.

MV Ramana, Executive Vice President and Head of Emerging Markets & India Business, DRL said, “We are delighted to partner with Integra LifeSciences. With the launch of DuraGen, we look forward to building our presence in the segment of regenerative technologies and making a difference to the lives of patients undergoing neurosurgery.”

“Our market-leading DuraGen products have helped more than one million patients worldwide,” said Glenn Coleman, CFO and Corporate Vice President, International, Integra LifeSciences. “This collaboration will allow us to continue to expand patient access globally and provide innovative regenerative technology solutions to neurosurgeons and patients in India.”

The DuraGen product line offers Duraplasty Solutions meant for the repair of the dura mater. Dura mater is a thick membrane that surrounds the brain and spinal cord, and contains the cerebrospinal fluid (CSF).

DuraGen Plus Dural Regeneration Matrix is indicated as a dural substitute for the repair of dura mater. It offers a simple technique for precise placement of the matrix as an on lay graft in cranial and spinal procedures, and easily conforms to the complex surfaces of exposed neural tissue. It provides effective protection against CSF leakage with suture less closure and is fully resorbed and replaced by native tissue with complete dural closure.

Suturable DuraGen matrix is a versatile graft that can be sutured and is designed for repairing dural defects where mechanical anchoring of the graft is preferred. This offers excellent suture retention with all the benefits of DuraGen Plus Matrix.

Integra’s DuraGen products have been implanted in more than 1.8 million patients worldwide to effect dural closure following neurosurgical procedures. Integra manufactures the DuraGen family of products based on its proprietary Ultra Pure Collagen technology platform.

Comments are closed.